Primary central nervous system angiosarcoma: two case reports

Journal of Medical Case Reports

Louis B Nabors¹  Hassan M Fathallah-Shaykh¹  Joel K Cure³  Kristen O Riley²  Cheryl Ann Palmer¹  James R Hackney⁴ 

[1] Department of Neurology, University of Alabama at Birmingham, FOT 1020, Birmingham, AL, 35294, USA;Division of Neurosurgery, University of Alabama at Birmingham, FOT 1046, Birmingham, AL, 35294, USA;Department of Radiology, University of Alabama at Birmingham, JT N418, Birmingham, AL, 35294, USA;Division of Neuropathology, University of Alabama at Birmingham, PD6A 175, Birmingham, AL, 35294, USA

关键词: Temozolomide;    Bevacizumab;    Sarcoma;    Primary Central Nervous System (CNS) Tumors;    Angiosarcoma;   

Others  :  1195531
DOI  :  10.1186/1752-1947-6-251

 received in 2011-08-10, accepted in 2012-03-02,  发布年份 2012

【 摘 要 】

Introduction

Primary angiosarcoma of the brain is extremely rare; only 15 cases have been reported in adults over the last 25 years.

Case presentations

We describe two cases of primary angiosarcoma of the brain that are well characterized by imaging, histopathology, and immunohistochemistry. Case 1: our first patient was a 35-year-old woman who developed exophthalmos. Subtotal resection of a left extra-axial retro-orbital mass was performed. Case 2: our second patient was a 47-year-old man who presented to our facility with acute visual loss, word-finding difficulty and subtle memory loss. A heterogeneously-enhancing left sphenoid wing mass was removed. We also review the literature aiming at developing a rational approach to diagnosis and treatment, given the rarity of this entity.

Conclusions

Gross total resection is the standard of care for primary angiosarcoma of the brain. Adjuvant radiation and chemotherapy are playing increasingly recognized roles in the therapy of these rare tumors.

【 授权许可】

   
2012 Hackney et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Mena H, Ribas JL, Enzinger FM, Parisi JE: Primary angiosarcoma of the central nervous system. J Neurosurg 1991, 75:73-76.
• [2]Merimsky O, Lepechous C, Terrier P, Vanel D, Delord JP, LeCesne A: Primary sarcomas of the central nervous system. Oncology 2000, 58:210-214.
• [3]Paulus W, Slowik F, Jellinger K: Primary intracranial sarcomas: Histopathological features of 19 cases. Histopathol 1991, 18:395-402.
• [4]Antoniadis C, Selviaridis P, Zaramboukas T, Fountzilas G: Primary angiosarcoma of the brain: case report. Neurosurg 1996, 38:583-586.
• [5]Charman HP, Lowenstein DH, Cho KG, DeArmond SJ, Wilson CB: Primary cerebral angiosarcoma. J Neurosurg 1988, 68:806-810.
• [6]Cookston M, Cotter GW, Schlitt M, Bastian FD: Primary angiosarcoma of the brain. South Med J 1991, 84:517-520.
• [7]Fuse T, Takagi T, Hirose M: Primary intracranial epithelioid angiosarcoma. Neurol Med Chir (Tokyo) 1995, 35:364-368.
• [8]Muhlau M, Schlegel J, von Einsiedel HG, Conrad B, Sander D: Multiple progressive intracerebral hemorrhages due to an angiosarcoma: a case report. Eur J Neurol 2003, 10:741-742.
• [9]Lach B, Benoit BG: Primary composite angiogenic leiomyosarcoma-epitheloid angiosarcoma of the brain. Ultrastruct Pathol 2000, 24:339-346.
• [10]Grimer R, Judson I, Peake D, Seddon B: Guidelines for the management of soft tissue sarcomas. Sarcoma 2010, 2010:1-15.
• [11]Penel N, Van Glabbeke M, Marreaud S, Ouali M, Blay JY, Hohenberger P: Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. Ann Oncol 2011, 22:1266-1272.
• [12]Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M, Isambert N, Peyrade F, Chevreau C, Bompas E, Brain EG, Blay JY: Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study. J Clin Oncol 2008, 26:5269-5274.
• [13]Schlemmer M, Reichardt P, Verweij J, Hartmann JT, Judson I, Thyss A, Hogendoorn PC, Marreaud S, Van Glabbeke M, Blay JY: Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 2008, 44:2346-2433.
• [14]Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27:4733-4740.
• [15]Park MS, Ravi V, Araujo DM: Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. Curr Opin Oncol 2010, 22:351-355.